A new market research report on the In Vitro Diagnostic market is now available in the reportlinker.com catalogue. The IVD services have greatly contributed to the global diagnostic industry during the past few years. The IVD market has been growing rapidly worldwide mainly on the back of factors, such as technological advancements, significant developments in diagnostic services, and active private sector participation. Other factors, such as increasing disease prevalence and high disposable income have also contributed to the development of IVD services industry, which was estimated to have reached US$ 44 Billion in 2010.
According to the new research report “Global In Vitro Diagnostic Market Analysis”, the global IVD services industry is likely to grow at a CAGR of around 5% during 2011-2013 to reach around US$ 52 Billion by the end of 2013. Innovation in technology is expected to play a vital role in the future and in this regard, the report includes an extensive research and analysis of all the segments of the IVD services industry.
T2 Biosystems, a company developing next-generation medical diagnostic products, can qualitatively and quantitatively measure an analyte in a dirty sample such as whole blood. This unique, non-optical detector, which combines magnetic resonance with nanoparticles and molecular probes can perform rapid testing for pathogens that currently require days for a culture result– such as fungus and bacteria. It also delivers a high level of accuracy and speed with central lab quality results, regardless of the setting. All of the tests can be run on one instrument in the lab, the clinic, or the physician’s office to provide new and improved diagnostic data to inform clinical decision-making.
diaDexus, Inc., a diagnostics company focused on the development and commercialization of in vitro diagnostic products addressing unmet needs in cardiovascular disease recently announced FDA clearance for marketing the new automated Plac Test, a blood test that helps identify individuals at increased risk of suffering a heart attack or stroke, the #1 and #3 causes of death respectively in the U.S. They were a presenting company at OneMedForum SF 2011.
Among the key constituents of the global IVD market, point-of-care segment has the largest part followed by immunochemistry and molecular diagnostics. As healthcare spending is increasing across the globe, these segments are likely to witness robust growth in their revenue patterns. Tests for diseases, such as diabetes, cardiovascular, and cancer are providing strong support to the industry developments. Moreover, the influenza diagnostic services are expected to provide momentum to the global IVD industry during the forecast period (2011-2013).
Other companies making advancements in the field of In Vitro Diagnostics include but are not limited to Neurotez, and ZS Pharma.